Macular Edema News and Research

RSS
Ranibizumab drug reverses diabetes-related blindness

Ranibizumab drug reverses diabetes-related blindness

Retinal function affected early in Type 1, 2 diabetes

Retinal function affected early in Type 1, 2 diabetes

LSDF announces $1.2 million in grants to foster advancement of promising health-related technologies

LSDF announces $1.2 million in grants to foster advancement of promising health-related technologies

Welch Allyn, LKC Technologies sign distribution agreement for RETeval DR screening device

Welch Allyn, LKC Technologies sign distribution agreement for RETeval DR screening device

IRIDEX's China distributor secures large tender to supply ophthalmology laser equipment

IRIDEX's China distributor secures large tender to supply ophthalmology laser equipment

Eylea receives Health Canada approval for treatment of CRVO and DME

Eylea receives Health Canada approval for treatment of CRVO and DME

iCo Therapeutics announces corporate update and Q3 2014 financial results

iCo Therapeutics announces corporate update and Q3 2014 financial results

Health Canada approves Lucentis (ranibizumab) for myopic CNV

Health Canada approves Lucentis (ranibizumab) for myopic CNV

Hercules Technology Growth Capital issues advance payment to Alimera Sciences

Hercules Technology Growth Capital issues advance payment to Alimera Sciences

Alimera announces FDA approval of ILUVIEN for treatment of diabetic macular edema

Alimera announces FDA approval of ILUVIEN for treatment of diabetic macular edema

EYLEA Injection gets approval in Japan for treatment of myopic CNV

EYLEA Injection gets approval in Japan for treatment of myopic CNV

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

New way to reduce abnormal blood vessel growth and leakage in eye

New way to reduce abnormal blood vessel growth and leakage in eye

iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics reports financial results for second quarter 2014

Research demonstrates that African Americans bear heavier burden of DME

Research demonstrates that African Americans bear heavier burden of DME

KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron announces FDA approval of EYLEA Injection for DME treatment

Regeneron announces FDA approval of EYLEA Injection for DME treatment